CDH2 and cancer: Cancer cells undergoing EMT display both morphological and molecular alterations [36], which is evidenced by the downregulation of epithelial markers, such as E-cadherin and ZO-1, and upregulation of mesenchymal markers, including N-cadherin, vimentin, fibroblast-specific protein 1, and fibronectin [35].